#China #Shanghai #Biopharma #WuXi Biologics #CRDMO

WuXi Biologics Triumphs at Asia-Pacific Biopharma Excellence Awards

In a stunning display of excellence, WuXi Biologics has taken home five prestigious awards at the 2025 Asia-Pacific Biopharma Excellence Awards (ABEA), held in April 2025. This recognition underscores the company's commitment to advancing the biotechnology sector and marks the seventh occasion it has been honored by this influential awards program.

Among the accolades received, WuXi Biologics was awarded the Best Contract Development and Manufacturing Organization, a testament to its leadership in providing comprehensive contract services. The organization also garnered awards for Best Aseptic Fill-Finish Packaging CMO of the Year, Best Aseptic Fill-Finish Packaging Supplier Award for Drug Delivery Systems, Best New Modalities Manufacturing Company, and the Best Bioprocessing Supplier Award for Cell Line Development and Characterization.

WuXi Biologics was not only recognized for its manufacturing prowess but also for its innovative technologies designed to expedite drug development processes. The company boasts a robust portfolio that includes 151 bispecifics, 194 antibody-drug conjugates (ADCs), 80 fusion proteins, and 24 vaccines. WuXi Biologics has effectively reduced the timeline for monoclonal antibody projects, achieving a significant milestone of transitioning from DNA to Investigational New Drug (IND) applications in just nine months and completing projects for autoimmune diseases in an accelerated six months. This impressive efficiency is supported by advanced single-use technology (SUT) that has scaled their manufacturing capabilities from 4,000 liters to 16,000 liters, all while maintaining an exceptional 99% success rate during the period from 2022 to 2024.

A key contributor to these successes is WuXi Biologics' renowned WuXia™ mammalian cell line platform, which can produce yields of up to 11 g/L. This platform has been widely accepted by the global industry and regulatory bodies, generating over 900 cell lines that express a variety of monoclonal antibodies, bispecific antibodies, fusion proteins, and other recombinant proteins essential for clinical and commercial applications. Innovations like WuXiaADCC Plus™, which enhances antibody-dependent cellular cytotoxicity (ADCC) responses, and WuXia RidGS™, a high-yield glutamine synthetase-knockout CHO expression system, are examples of how WuXi Biologics meets the diverse needs of its clients.

Dr. Chris Chen, the CEO of WuXi Biologics, emphasized the importance of these awards, stating, "The numerous accolades earned by WuXi Biologics stand as a powerful testament to the value we deliver to global clients and the broader industry. Through our relentless pursuit of excellence, uncompromising quality standards, visionary leadership, and the dedication of our talented global team, we remain steadfast in enabling partners to accelerate groundbreaking therapies—bringing life-changing treatments to patients around the world."

Sponsored by IMAPAC, a leading consulting firm in the biopharmaceutical industry, the ABEA acknowledges leaders in biomanufacturing, biologistics, and clinical trials. These awards are determined by a transparent process involving community nominations, rigorous internal evaluations, and final votes from global industry participants, ensuring that the winners reflect the true sentiments of the biopharma community.

WuXi Biologics' journey in the biopharmaceutical sector is marked by its unwavering commitment to quality and sustainability, aiming to drive innovations that support environmentally friendly practices without compromising their mission. As of the end of 2024, WuXi Biologics employs over 12,000 skilled professionals across various regions, including China, the United States, Ireland, Germany, and Singapore, further paving the way for future advancements in biologics discovery, development, and manufacturing.

As WuXi Biologics continues to grow, it aims to deliver in-depth and integrated solutions to its partners, maintaining a leadership position in accelerating life-altering therapies for patients globally. For further details, visit their website at www.wuxibiologics.com.